Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Cooley

Showing results (51-60 of 87) with videos related to

Pageof 9
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 30, 2009
Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantationJill C Beck, John E Wagner, Todd E DeFor, et al.
Cancer Immunology, Immunotherapy : CII|September 8, 2010
Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancersMelissa A Geller, Sarah Cooley, Peter A Argenta, et al.
Transplantation and Cellular Therapy|April 10, 2021
Early Adaptive Natural Killer Cell Expansion Is Associated with Decreased Relapse After Autologous Transplantation for Multiple MyelomaAimee M Merino, Rohtesh S Mehta, Xianghua Luo, et al.
Cancer Immunology Research|May 23, 2018
Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37Dhifaf Sarhan, Keli L Hippen, Amanda Lemire, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 14, 2011
T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcomeDaniel Weisdorf, Sarah Cooley, Steven Devine, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 18, 2016
Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation OutcomesGretchen A Hoff, Johannes C Fischer, Katharine Hsu, et al.
Blood|June 21, 2007
Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI aloneJeffrey S Miller, Daniel J Weisdorf, Linda J Burns, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2014
Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemiaSarah Cooley, Daniel J Weisdorf, Lisbeth A Guethlein, et al.
Cancer Immunology, Immunotherapy : CII|April 10, 2026
A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemiaMarina Konopleva, Vijaya Raj Bhatt, Ioannis Mantzaris, et al.
Blood|February 24, 2007
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCTJeffery S Miller, Sarah Cooley, Peter Parham, et al.
Pageof 9

Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 30, 2009
Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantationJill C Beck, John E Wagner, Todd E DeFor, et al.
Cancer Immunology, Immunotherapy : CII|September 8, 2010
Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancersMelissa A Geller, Sarah Cooley, Peter A Argenta, et al.
Transplantation and Cellular Therapy|April 10, 2021
Early Adaptive Natural Killer Cell Expansion Is Associated with Decreased Relapse After Autologous Transplantation for Multiple MyelomaAimee M Merino, Rohtesh S Mehta, Xianghua Luo, et al.
Cancer Immunology Research|May 23, 2018
Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37Dhifaf Sarhan, Keli L Hippen, Amanda Lemire, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 14, 2011
T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcomeDaniel Weisdorf, Sarah Cooley, Steven Devine, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 18, 2016
Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation OutcomesGretchen A Hoff, Johannes C Fischer, Katharine Hsu, et al.
Blood|June 21, 2007
Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI aloneJeffrey S Miller, Daniel J Weisdorf, Linda J Burns, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2014
Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemiaSarah Cooley, Daniel J Weisdorf, Lisbeth A Guethlein, et al.
Cancer Immunology, Immunotherapy : CII|April 10, 2026
A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemiaMarina Konopleva, Vijaya Raj Bhatt, Ioannis Mantzaris, et al.
Blood|February 24, 2007
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCTJeffery S Miller, Sarah Cooley, Peter Parham, et al.
Pageof 9